Atopic Dermatitis
📧 Sign up to get email alerts when something new happens for Atopic Dermatitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-28Clinical Trial Results: A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) [Phase 3]
Phase 3 trial evaluating rocatinlimab (AMG 451) in adolescents with moderate-to-severe atopic dermatitis has completed with posted results.
-
EMA approval · 2026-08-18EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie
The EMA has authorised Dupixent (dupilumab) for multiple indications including atopic dermatitis, prurigo, esophageal diseases, asthma, and …
-
EMA approval · 2026-08-06EMA Authorised: Cibinqo (abrocitinib) — Pfizer Europe MA EEIG
EMA confirms authorisation of Cibinqo (abrocitinib) for atopic dermatitis in Europe.
-
CLINICAL_TRIALS trial_result · 2026-08-06Clinical Trial Results: A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) [Phase 3]
Phase 3 clinical trial evaluating rocatinlimab in combination with topical therapies for adults with moderate-to-severe atopic dermatitis; s…
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of tralokinumab in moderate-to-severe atopic hand eczema and related atopic dermatitis sh…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-03EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.
EMA has authorised Opzelura (ruxolitinib phosphate) for use in vitiligo and atopic dermatitis, with Incyte Biosciences Distribution B.V. as …
-
CLINICAL_TRIALS trial_result · 2026-07-24Clinical Trial Results: A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) [Phase 3]
Phase 3 trial results evaluating Rocatinlimab in adolescents with moderate-to-severe atopic dermatitis have been completed with posted resul…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) [Phase 3]
Phase 3 trial results for rocatinlimab in moderate-to-severe atopic dermatitis (ROCKET-IGNITE) have been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) [Phase 3]
Phase 3 trial evaluating rocatinlimab's effect on vaccine antibody response in adults with moderate-to-severe atopic dermatitis has complete…
-
CLINICAL_TRIALS trial_result · 2026-07-21Clinical Trial Results: BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort [NA]
Clinical trial results comparing broadband vs narrowband phototherapy for eczema within the CACTI cohort; study terminated with results post…
-
EMA approval · 2026-07-17EMA Authorised: Anzupgo (Delgocitinib) — LEO Pharma A/S
Anzupgo (delgocitinib) has been authorised by the EMA for dermatitis/eczema with LEO Pharma A/S as the marketing authorization holder.
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis [Phase 3]
Phase 3 trial results for lebrolikizumab in adults and adolescents with moderate-to-severe atopic dermatitis show effectiveness and safety d…
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…
-
CLINICAL_TRIALS trial_result · 2026-07-13Clinical Trial Results: Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis [Phase 2]
Phase 2 proof-of-concept study evaluating rilzabrutinib in adults with moderate-to-severe atopic dermatitis has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Results: A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) [Phase 3]
Phase 3 study results for rocatinlimab monotherapy in moderate-to-severe atopic dermatitis completed; results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-16Clinical Trial Results: Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. [Phase 2]
Phase 2 long-term study of GSK1070806 in atopic dermatitis has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis [Phase 4]
Phase 4 clinical trial results on longitudinal endotyping of atopic dermatitis using transcriptomic skin analysis.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis [Phase 2]
Phase 2 dose-finding study results for GSK1070806 in adults with moderate to severe atopic dermatitis; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis [Phase 4]
Phase 4 trial evaluating dupilumab to improve circadian function, sleep, and pruritus in children with moderate-to-severe atopic dermatitis.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Study Evaluating TRIV-509 in Atopic Dermatitis [Phase 2]
Phase 2 clinical trial update for TRIV-509 in atopic dermatitis.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Phase 1 Study of GS101 Injection [Phase 1]
A Phase 1 clinical trial update for GS101 Injection investigating safety and tolerability in Atopic Dermatitis, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study [NA]
A prospective, multicenter real-world study assessing the efficacy and safety of switching to Ivarmacitinib in adults with moderate-to-sever…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis
A University of Pennsylvania-sponsored study is investigating filaggrin gene mutations in Latinx patients with atopic dermatitis, and the tr…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants [Phase 1]
A dose-escalation Phase 1 trial of HXN5003 in healthy participants is not yet recruiting, sponsored by Helixon Biotechnology (Suzhou) Co., L…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis [Phase 1]
Phase 1 clinical trial evaluating IBI3033 for moderate-to-severe atopic dermatitis; recruitment has not yet begun.